Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02265367 · ClinicalTrials.gov registry record · NA
Novel Medication as a Potential Smoking Cessation Aid
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT02265367: Completed NA study, sponsored by University of Minnesota.
NCT02265367 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02265367, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.
Primary Outcome
Subjects will be asked to abstain for five consecutive days during the third week of each intervention period with the percentage of confirmed abstinence days being the primary outcome measure
Interventions
- DRUG Placebo
- DRUG Levomilnacipran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-05 |
| Phase | NA |
What the finished NCT02265367 record still lists
NCT02265367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02265367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02265367 about?
NCT02265367 is a clinical study titled "Novel Medication as a Potential Smoking Cessation Aid". The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.
What is the current status of trial NCT02265367?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2015-01. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02265367?
The interventions under investigation include: Placebo (DRUG), Levomilnacipran (DRUG).
Who is sponsoring clinical trial NCT02265367?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02265367's enrollment target sits among peer trials
56 1262nd of 2000 higher than 737 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia